Baker Bros. Advisors’s Akari Therapeutics AKTX Stock Holding History

Baker Bros. Advisors’s Portfolio AKTX Stock Details AKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-73	Closed	-$115K	–	100
2018 Q2	$115K	Sell	73 -352	-83%	-$553K	﹤0.01%	117
2018 Q1	$618K	Sell	425 -446	-51%	-$963K	0.01%	108
2017 Q4	$3.02M	Buy	871 +250	+40%	+$964K	0.03%	89
2017 Q3	$3.05M	Hold	621	–	–	0.02%	87
2017 Q2	$2.29M	Hold	621	–	–	0.02%	82
2017 Q1	$5.5M	Hold	621	–	–	0.05%	63
2016 Q4	$3.5M	Hold	621	–	–	0.03%	73
2016 Q3	$4.23M	Hold	621	–	–	0.04%	72
2016 Q2	$6.7M	Buy	621 +126	+25%	+$1.62M	0.07%	65
2016 Q1	$5.54M	Hold	495	–	–	0.06%	71
2015 Q4	$5.74M	Hold	495	–	–	0.05%	74
2015 Q3	$9.5M	Buy	+495	New	+$5.86M	0.09%	63
2015 Q1	–	Sell	-84	Closed	-$3.23M	–	131
2014 Q4	$3.23M	Hold	84	–	–	0.03%	85
2014 Q3	$4.11M	Hold	84	–	–	0.05%	69
2014 Q2	$3.71M	Hold	84	–	–	0.05%	78
2014 Q1	$4.37M	Buy	+84	New	+$4.75M	0.06%	78

Other funds holding AKTX

Hikari Power Tokyo, Japan $855M AUM 14.24% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

ECM

Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return

AAMU

Amundi Asset Management US Boston, Massachusetts $131B AUM 73.57% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

Parallax Volatility Advisers San Francisco, California $38.6B AUM 45.89% 1-Year Est. Return

Truvestments Capital Sarasota, Florida $554M AUM 32.49% 1-Year Est. Return

LTFS

Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 27.61% 1-Year Est. Return

Baker Bros. Advisors's AKTX Position: Q3 2018 in Review

Baker Bros. Advisors sold out of Akari Therapeutics (AKTX) in Q3 2018, closing a stake of 73 shares — an estimated $115K sold.

Baker Bros. Advisors first reported a position in AKTX in Q1 2014 and held it in 16 quarters. The position peaked at $9.5M in Q3 2015. 10 funds tracked by Wall St. Rank hold AKTX as of Q3 2018.

Baker Bros. Advisors reported no remaining Akari Therapeutics position as of Q3 2018 after selling out during the quarter.
Baker Bros. Advisors sold 73 Akari Therapeutics shares in Q3 2018, an estimated $115K.
Baker Bros. Advisors first reported a position in Akari Therapeutics in Q1 2014 and held it in 16 quarters.
Baker Bros. Advisors's Akari Therapeutics position peaked at $9.5M in Q3 2015.
10 funds tracked by Wall St. Rank held Akari Therapeutics as of Q3 2018.

Based on Baker Bros. Advisors's 13F filing for Q3 2018, filed 14 Nov 2018.